Recent Developments in Pancreatic Cancer Treatment
The 200th patient treatment using the OncoSil device has been announced by OncoSil Medical Ltd. This marks a noteworthy achievement for the company's brachytherapy technology, which is used to treat locally advanced, unresectable pancreatic cancer. The procedure, which was performed at the Royal Adelaide Hospital, demonstrates how the gadget is becoming more and more well-liked in the medical community as well as in clinical trials and commercial applications across the globe. As more patients are enrolled in therapy, OncoSil Medical's strategy to break into international markets is gaining traction.
Meanwhile, the 5th patient has been treated in the ongoing PANCOSIL Investigator-Initiated Clinical Trial. PANCOSIL is a Netherlands-based Investigator-Initiated Clinical Trial conducted at AMC Medical Centre in Amsterdam in collaboration with OncoSil Medical. The trial targets patients with n locally advanced unresectable pancreatic cancer, testing the safety and feasibility of CT-guided percutaneous radionuclide therapy (RNT) with the OncoSil™ device
The OncoSil Device Progress in Treating Patients
- 200 patients have been treated
- Devices are increasingly viewed as safe as no major incident is reported
- A rising share of treatments encouraging commercialisation
What is the Importance of this Milestone for OncoSil Medical?
- For Oncosil to gain broader acceptance worldwide and among regulators, it needs to conduct more clinical trials that expands the current indication. Reaching the 200th treatment is significant not because of the number, but rather because the company has time to review further evidence and tweak its product to deliver first-class care to patients going forward.
- With its special designation from the Food and Drug Administration (FDA) in the United States, it is important to certify further the safety of Oncosil to support its application at the FDA and ensure that consumers who are at risk of distal cholangiocarcinoma can benefit from this treatment.
- OncoSil is approved in over 35 countries and its safety record will make the product increasingly legitimate for both medical doctors and practitioners who are currently using the Oncosil (ASX: OSL) device.
Future Outlook on OncoSil Medical
Over the medium term, this will begin reflecting in Oncosil's (ASX: OSL) share price, supporting long-term price dynamics. Furthermore, the results will equally reinforce confidence in the regulators that Oncosil is safe to use and can be used in a variety of contexts. However, the treatment of 200 people will equally support Oncosil’s commercialization efforts across Asia, the Middle East, and Europe.
